Difference between revisions of "Olverembatinib (HQP-1351)"
Jump to navigation
Jump to search
(Created page with "==Mechanism of action== Third-generation TKI ==Diseases for which it is used== *Chronic myeloid leukemia ==History of changes in NMPA indication== *2021-11: Initial cond...") |
m (Jwarner moved page Olverembatinib (HQP1351) to Olverembatinib (HQP-1351): naming standardization) |
(No difference)
| |
Latest revision as of 16:31, 7 September 2023
Mechanism of action
Third-generation TKI
Diseases for which it is used
History of changes in NMPA indication
- 2021-11: Initial conditional approval for the treatment of adult patients with TKI-resistant CML-CP or CML-AP harboring the T315I mutation as confirmed by a validated diagnostic test. (Based on HQP1351CC203)
Also known as
- Code name: HQP-1351